6 December 2022
Malaysia
Evusheld Monoclonal Antibody Combination Now Available In Malaysia’s Private Market For Prevention Of Covid-19 In High-Risk Individuals
KUALA LUMPUR, Dec 6 – AstraZeneca’s Evusheld (tixagevimab and cilgavimab, MAL 22056042ACR2), a monoclonal antibody combination, has been launched in Malaysian private hospitals for the prevention of Covid-19 in high-risk individuals. The National Pharmaceutical Regulatory Agency (NPRA) had granted conditional registration for Evusheld in May this year for the pre-exposure prophylaxis (prevention) of Covid-19 in … Continue reading Evusheld Monoclonal Antibody Combination Now Available In Malaysia’s Private Market For Prevention Of Covid-19 In High-Risk Individuals